daratumumab,bortezomib
janssen,takeda 
['daratumumab', 'mmsm']
among patients with newly diagnosed, transplant-eligible #myeloma treated in a phase 2 study, induction &amp; consolidation with daratumumab + the rvd regimen outperformed rvd alone in minimal residual disease and progression-free survival. #asco22 #mmsm 
Oncology news and insights from leading researchers and cancer centers.